Long-term experience with low dose methotrexate in rheumatoid arthritis
Identifieur interne : 002D88 ( Main/Exploration ); précédent : 002D87; suivant : 002D89Long-term experience with low dose methotrexate in rheumatoid arthritis
Auteurs : M. Tishler [Israël] ; D. Caspi [Israël] ; M. Yaron [Israël]Source :
- Rheumatology International [ 0172-8172 ] ; 1993-08-01.
English descriptors
- KwdEn :
- Teeft :
- American rheumatism association, Arthritis, Arthritis rheum, Aviv, Carcinoma, Clinical characteristics, Current study, Daily dosage, Dosage adjustment, Entire cohort, Higher probability, Ichilov hospital, Latter group, Long term, Long term treatment, Lung cancer, Major complications, Methotrexate, Mild improvement, Minor side effects, Moderate improvement, Nsaid, Other drugs, Ovarian carcinoma, Overall probability, Overall response, Preliminary criteria, Previous study, Prospective study, Remission, Rheum, Rheumatoid, Rheumatoid arthritis, Same physician, Second part, Septic arthritis, Seronegative patients, Seropositive patients, Side effects, Study period, Toxic effects, Toxicity, Transaminase levels, Whole group.
Abstract
Summary: One hundred twenty-six patients with rheumatoid arthritis (RA) were treated with weekly low doses of methotrexate (MTX) for a mean period of 36.8 months (range 13–110 months). The overall probability of continuing with MTX therapy was 72% at 2 and 3 years, 67% at 4 years and 65% at 5–7 years. Seronegative patients had a higher probability of continuing therapy than seropositive patients (P<0.05). Out of the whole group, 8% showed no improvement, 16% showed mild improvement, and 30% showed moderate improvement, and 45% experienced marked improvement. Eight patients (6%) of the latter group achieved complete clinical remission. In the course of the follow-up period there was a significant decrease in the mean daily dosage of prednisone and NSAIDs. Minor side effects were common (68%), but therapy was discontinued in only 27 patients (21%) because of major complications. In most of them (25 out of 27) these occured within the first 24 months of therapy. Although malignancy was revealed in 5 patients during the follow-up period, its occurrence did not differ from expected rates.
Url:
DOI: 10.1007/BF00290296
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001E88
- to stream Istex, to step Curation: 001E88
- to stream Istex, to step Checkpoint: 001B70
- to stream Main, to step Merge: 002E53
- to stream Main, to step Curation: 002D88
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-term experience with low dose methotrexate in rheumatoid arthritis</title><author><name sortKey="Tishler, M" sort="Tishler, M" uniqKey="Tishler M" first="M." last="Tishler">M. Tishler</name></author><author><name sortKey="Caspi, D" sort="Caspi, D" uniqKey="Caspi D" first="D." last="Caspi">D. Caspi</name></author><author><name sortKey="Yaron, M" sort="Yaron, M" uniqKey="Yaron M" first="M." last="Yaron">M. Yaron</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3DC51D5996C878142ED25B0BEE9BBA96A9E4A375</idno><date when="1993" year="1993">1993</date><idno type="doi">10.1007/BF00290296</idno><idno type="url">https://api.istex.fr/ark:/67375/1BB-8S7FV8LB-F/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001E88</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001E88</idno><idno type="wicri:Area/Istex/Curation">001E88</idno><idno type="wicri:Area/Istex/Checkpoint">001B70</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001B70</idno><idno type="wicri:doubleKey">0172-8172:1993:Tishler M:long:term:experience</idno><idno type="wicri:Area/Main/Merge">002E53</idno><idno type="wicri:Area/Main/Curation">002D88</idno><idno type="wicri:Area/Main/Exploration">002D88</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long-term experience with low dose methotrexate in rheumatoid arthritis</title><author><name sortKey="Tishler, M" sort="Tishler, M" uniqKey="Tishler M" first="M." last="Tishler">M. Tishler</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Rheumatology, Tel Aviv Medical Center, Tel Aviv University Sackler School of Medicine, Tel Aviv</wicri:regionArea><wicri:noRegion>Tel Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Caspi, D" sort="Caspi, D" uniqKey="Caspi D" first="D." last="Caspi">D. Caspi</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Rheumatology, Tel Aviv Medical Center, Tel Aviv University Sackler School of Medicine, Tel Aviv</wicri:regionArea><wicri:noRegion>Tel Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Yaron, M" sort="Yaron, M" uniqKey="Yaron M" first="M." last="Yaron">M. Yaron</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Rheumatology, Tel Aviv Medical Center, Tel Aviv University Sackler School of Medicine, Tel Aviv</wicri:regionArea><wicri:noRegion>Tel Aviv</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Rheumatology International</title><title level="j" type="sub">Clinical and Experimental Investigations</title><title level="j" type="abbrev">Rheumatol Int</title><idno type="ISSN">0172-8172</idno><idno type="eISSN">1437-160X</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="1993-08-01">1993-08-01</date><biblScope unit="volume">13</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="103">103</biblScope><biblScope unit="page" to="106">106</biblScope></imprint><idno type="ISSN">0172-8172</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0172-8172</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Longterm treatment</term><term>Methotrexate</term><term>Rheumatoid arthritis</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>American rheumatism association</term><term>Arthritis</term><term>Arthritis rheum</term><term>Aviv</term><term>Carcinoma</term><term>Clinical characteristics</term><term>Current study</term><term>Daily dosage</term><term>Dosage adjustment</term><term>Entire cohort</term><term>Higher probability</term><term>Ichilov hospital</term><term>Latter group</term><term>Long term</term><term>Long term treatment</term><term>Lung cancer</term><term>Major complications</term><term>Methotrexate</term><term>Mild improvement</term><term>Minor side effects</term><term>Moderate improvement</term><term>Nsaid</term><term>Other drugs</term><term>Ovarian carcinoma</term><term>Overall probability</term><term>Overall response</term><term>Preliminary criteria</term><term>Previous study</term><term>Prospective study</term><term>Remission</term><term>Rheum</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Same physician</term><term>Second part</term><term>Septic arthritis</term><term>Seronegative patients</term><term>Seropositive patients</term><term>Side effects</term><term>Study period</term><term>Toxic effects</term><term>Toxicity</term><term>Transaminase levels</term><term>Whole group</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: One hundred twenty-six patients with rheumatoid arthritis (RA) were treated with weekly low doses of methotrexate (MTX) for a mean period of 36.8 months (range 13–110 months). The overall probability of continuing with MTX therapy was 72% at 2 and 3 years, 67% at 4 years and 65% at 5–7 years. Seronegative patients had a higher probability of continuing therapy than seropositive patients (P<0.05). Out of the whole group, 8% showed no improvement, 16% showed mild improvement, and 30% showed moderate improvement, and 45% experienced marked improvement. Eight patients (6%) of the latter group achieved complete clinical remission. In the course of the follow-up period there was a significant decrease in the mean daily dosage of prednisone and NSAIDs. Minor side effects were common (68%), but therapy was discontinued in only 27 patients (21%) because of major complications. In most of them (25 out of 27) these occured within the first 24 months of therapy. Although malignancy was revealed in 5 patients during the follow-up period, its occurrence did not differ from expected rates.</div></front></TEI><affiliations><list><country><li>Israël</li></country></list><tree><country name="Israël"><noRegion><name sortKey="Tishler, M" sort="Tishler, M" uniqKey="Tishler M" first="M." last="Tishler">M. Tishler</name></noRegion><name sortKey="Caspi, D" sort="Caspi, D" uniqKey="Caspi D" first="D." last="Caspi">D. Caspi</name><name sortKey="Yaron, M" sort="Yaron, M" uniqKey="Yaron M" first="M." last="Yaron">M. Yaron</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D88 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002D88 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:3DC51D5996C878142ED25B0BEE9BBA96A9E4A375
|texte= Long-term experience with low dose methotrexate in rheumatoid arthritis
}}
| This area was generated with Dilib version V0.6.33. |  |